All Stocks/Healthcare/TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD

TEVA
HealthcareDrug Manufacturers - Specialty & Generic Website
Price ChartPowered by TradingView
Ask about TEVAAI research agent
Alpha Score BreakdownHow it works →

Alpha Score of 63 reflects moderate overall profile with strong momentum, strong value, weak quality, moderate sentiment.

Momentum
76
Strong
Value
77
Strong
Quality
42
Weak
Sentiment
50
Weak
Key StatisticsUpdated Apr 15
P/E Ratio
11.81
Forward P/E
–
PEG Ratio
–
EPS (TTM)
2.65
Dividend Yield
–
Beta
0.38
Revenue (TTM)
–
Net Margin
8.17%
ROE
19.97%
Debt / Equity
2.12
52W High
$36.25
52W Low
$12.82
Insider ActivitySEC Form 4 filings
Buys (90d)
0
Sells (90d)
7
Net $ (90d)
$-4.1M
Unique insiders
7
DateInsiderRoleTypeSharesValue
Mar 17, 26Sabag MarkSee "Remarks"SELL62.1K$1.9M
Mar 5, 26Jover PlacidSee "Remarks"SELL14.2K$448K
Mar 5, 26Francis Richard DPresident and CEOSELL20.0K$634K
Mar 5, 26Fox ChristineEVP, U.S. CommercialSELL7.9K$251K
Mar 5, 26Hughes Eric ASee "Remarks"SELL9.5K$302K
Mar 5, 26Daniell RichardEVP, Europe CommercialSELL17.3K$548K
Mar 5, 26Savage BrianInterim Chief Legal OfficerSELL1.1K$36K
Top Institutional HoldersFrom 13F filings
FundShares HeldPosition ValueAction (latest Q)
Citadel
Ken Griffin
8.09M$252.51MNEW
D.E. Shaw
David Shaw
819K$25.55MNEW
Blackstone137K$4.28MNEW
Greenlight Capital
David Einhorn
268K$2.80MNEW
ARK Invest
Cathie Wood
68K$2.06M-35%
Marshall Wace27K$830.2KNEW
Point72
Steve Cohen
7K$212.2KNEW
Duquesne Family Office
Stanley Druckenmiller
5.87M$183.4KNEW
Politicians who traded TEVAFrom Senate & House PTRs
PoliticianDateTypeAmount
Greg Gianforte
MT
2020-11-13purchase$15k – $50k
Donna Shalala
FL
2020-05-07sale$1k – $15k
Patty Murray
D-WA
2017-06-15sale$1k – $15k
Angus S King, .2016-10-19sale$1k – $15k
K. Michael Conaway
TX
2016-09-12sale$1k – $15k
K. Michael Conaway
TX
2016-05-04sale$1k – $15k
K. Michael Conaway
TX
2015-02-09sale$1k – $15k
Thomas MacArthur
NJ
2015-01-27sale$1k – $15k
About TEVA PHARMACEUTICAL INDUSTRIES LTD

Teva Pharmaceutical Industries Ltd. ADR is an American Depositary Receipt representing shares of the Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd., founded in 1901 and headquartered in Tel Aviv, Israel. The company develops, manufactures, markets, and distributes a broad portfolio of generic medicines and innovative biopharmaceutical products across the United States, Europe, Israel, and international markets. Its generic offerings span various dosage forms including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, creams, sterile products, hormones, high-potency drugs, and cytotoxics, often combined with medical devices. Teva specializes in key therapeutic areas such as the central nervous system with products like COPAXONE for multiple sclerosis, AJOVY for migraine prevention, and AUSTEDO for movement disorders; respiratory treatments including ProAir RespiClick, QVAR RediHaler, and DuoResp Spiromax; and oncology with biosimilars like Truxima and Herzuma, plus BENDEKA and TREANDA injections. Additionally, it supplies active pharmaceutical ingredients, provides contract manufacturing services, and operates a U.S.-based generic and specialty drug distribution platform through Anda. Teva's diverse operations position it as a leading global player in accessible healthcare solutions, serving patients with both cost-effective generics and specialized therapies.

CEO
Mr. Richard D. Francis
Employees
31,173
Quick Facts
Exchange–
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Market Cap–
Avg Volume1.11M
Key Dates

Earnings calendar coming soon. Subscribe to get notified when TEVA reports next.

Get earnings alerts →